Connect your AI

Vertex Pharmaceuticals VRTX Share Buybacks

Share Buybacks at other companies

AbbVieABBV

$1.49B+54.9%

Vera TherapeuticsVERA

$0-100%

Other financials

Income statement

Revenue$3.0B+7.8%

Gross profit$2.6B+7.8%

Operating income$1.1B+80.6%

Net income$1.0B+59.6%

EPS (diluted)$4.02+61.4%

Balance sheet

Cash & equivalents$5.5B+17.5%

Total debt$2.0B+20.5%

Total equity$19.4B+17.4%

Total assets$26.5B+15.8%

Cash flow

Operating cash flow$1.4B+74.4%

CapEx$133.4M+228%

Free cash flow$1.3B+66.4%

Valuation

Market cap$124.7B+7.8%

Enterprise value$121.19B+8.0%

P/E28.8×—

P/S10.2×+0.1×

Profitability

Gross margin86.2%+0.2pp

Operating margin38.3%—

Net margin35.5%—

FCF margin30.4%+20.2pp

Returns & leverage

Return on equity24.2%—

Debt / equity0.1×0.0×

Current ratio3×+0.4×

Where this comes from

Reported directly by Vertex Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vertex Pharmaceuticals's share buybacks.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Vertex Pharmaceuticals's share buybacks?: Vertex Pharmaceuticals (VRTX) reported share buybacks of $336.9M in Q1 2026.
How has Vertex Pharmaceuticals's share buybacks changed year-over-year?: Vertex Pharmaceuticals's share buybacks decreased by 20.9% year-over-year, from $426.1M to $336.9M.
What is the long-term trend for Vertex Pharmaceuticals's share buybacks?: Over 4 years (2021 to 2025), Vertex Pharmaceuticals's share buybacks has grown at a 9.1% compound annual growth rate (CAGR), from $1.43B to $2.02B.
What does share buybacks mean?: Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.